Compare PD & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | ANAB |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2019 | 2017 |
| Metric | PD | ANAB |
|---|---|---|
| Price | $12.55 | $44.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 12 |
| Target Price | $17.10 | ★ $58.09 |
| AVG Volume (30 Days) | ★ 1.6M | 501.4K |
| Earning Date | 11-25-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $489,207,000.00 | $169,467,000.00 |
| Revenue This Year | $8.16 | $135.45 |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | $7.77 | ★ N/A |
| Revenue Growth | 7.01 | ★ 196.42 |
| 52 Week Low | $11.13 | $12.21 |
| 52 Week High | $20.00 | $52.47 |
| Indicator | PD | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 46.84 |
| Support Level | $12.06 | $42.00 |
| Resistance Level | $12.77 | $47.36 |
| Average True Range (ATR) | 0.38 | 2.37 |
| MACD | 0.03 | -0.95 |
| Stochastic Oscillator | 35.06 | 19.77 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).